Skip to main content
. 2020 Apr 23;7(4):e723. doi: 10.1212/NXI.0000000000000723

Table 2.

Clinical characteristics of infants exposed to natalizumab during the third trimester of pregnancy

graphic file with name NEURIMMINFL2020027060t2.jpg